ORGO Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

172.65M

+36.31%

0.210

+425%

99.70M

+15%

-0.090

-47.06%

115.90M

+14.75%

-0.010

-90%

Estimates Revision

The market is revising Upward the revenue expectations for Organogenesis Holdings Inc. (ORGO) for FY2025, with the revenue forecasts being adjusted by 0.17% over the past three months. During the same period, the stock price has changed by 6.31%.

Revenue Estimates for FY2025

Revise Upward

+0.17%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+16.67%

In Past 3 Month

Stock Price

Go Up

+6.31%

In Past 3 Month

2 Analyst Rating

Wall Street analysts forecast ORGO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ORGO is 9.00 USD with a low forecast of 9.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

9.00

Averages

9.00

High

9.00

Current: 0.000

Low

9.00

Averages

9.00

High

9.00

BTIG

Buy

maintain

2025-12-26

Reason

BTIG

Price Target

2025-12-26

maintain

Buy

Reason

BTIG keeps a Buy rating and $9 price target on Organogenesis but notes that the firm's confidence on the stock as 2026 Top Pick is being reduced. BTIG cites CMS announcing that it would not implement the final Skin-Sub LCDs - Local Coverage Determinations - on January 1, 2026, noting that this unexpected update comes just 9 days after CMS announced that the MACs would be implementing the LCDs but with products classified into 3 categories - covered, non-covered, and 12-month status quo - even though the firm still believes that low-cost providers such as Organogenesis will be best-positioned in the market, the analyst tells investors in a research note.

BTIG

Buy

maintain

$7 -> $9

2025-11-20

Reason

BTIG

Price Target

$7 -> $9

2025-11-20

maintain

Buy

Reason

BTIG raised the firm's price target on Organogenesis to $9 from $7 and keeps a Buy rating on the shares. With the changes in reimbursement set to take effect in 2026, there will be clear share winners and share losers, and the firm believes that Organogenesis will be one of those that may be a share winner based on its current product pricing structure relative to the finalized pricing structure at $127.28 per cm, the analyst tells investors in a research note.

Morgan Stanley

Drew Ranieri

Hold

Maintains

$4 → $6

2025-03-05

Reason

Morgan Stanley

Drew Ranieri

Price Target

$4 → $6

2025-03-05

Maintains

Hold

Reason

Morgan Stanley raised the firm's price target on Organogenesis to $6 from $4 and keeps an Equal Weight rating on the shares, citing a "robust" Q4 report with visibility into a stronger financial performance in 2025. Though longer term drivers are tracking inline with expectations, the firm stays Equal Weight, citing local coverage determination overhangs and an implied back-end weighted ramp for 2025.

Valuation Metrics

The current forward P/E ratio for Organogenesis Holdings Inc (ORGO.O) is 22.07, compared to its 5-year average forward P/E of 35.24. For a more detailed relative valuation and DCF analysis to assess Organogenesis Holdings Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

35.24

Current PE

22.07

Overvalued PE

121.21

Undervalued PE

-50.73

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

14.17

Current EV/EBITDA

9.29

Overvalued EV/EBITDA

21.14

Undervalued EV/EBITDA

7.20

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

1.64

Current PS

1.09

Overvalued PS

2.98

Undervalued PS

0.31

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 1870.37% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areSelling! The selling amount has increased 1870.37% over the last month.

Sold

Bought

ORGO News & Events

Events Timeline

No data

News

7.0

01-08PRnewswire

Organogenesis Faces Securities Fraud Investigation, Stock Drops 10.14%

7.0

01-06Globenewswire

Organogenesis Faces Securities Fraud Investigation, Stock Drops 10.14%

5.0

01-05Newsfilter

Avista Healthcare Partners Promotes Three Key Executives in Investment Team

People Also Watch

Frequently Asked Questions

What is Organogenesis Holdings Inc (ORGO) stock price today?

The current price of ORGO is 4.21 USD — it has increased 0 % in the last trading day.

What is Organogenesis Holdings Inc (ORGO)'s business?

Organogenesis Holdings Inc. is a regenerative medicine company focused on the development, manufacture and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. It offers a portfolio of regenerative products to address patient needs across the continuum of care. Its wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for the treatment of DFUs; PuraPly AM as an antimicrobial barrier, cross-linked with extracellular matrix scaffold for a variety of wound types; and Affinity, Novachor and NuShield placental allografts to address a variety of wound sizes and types as a protective barrier and extracellular matrix scaffold. Its sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM and PuraPly SX for the management of open wounds in a surgical setting.

What is the price predicton of ORGO Stock?

What is Organogenesis Holdings Inc (ORGO)'s revenue for the last quarter?

Organogenesis Holdings Inc revenue for the last quarter amounts to 150.86M USD, increased 30.98 % YoY.

What is Organogenesis Holdings Inc (ORGO)'s earnings per share (EPS) for the last quarter?

Organogenesis Holdings Inc. EPS for the last quarter amounts to 0.11 USD, increased 22.22 % YoY.

What changes have occurred in the market's expectations for Organogenesis Holdings Inc (ORGO)'s fundamentals?

How many employees does Organogenesis Holdings Inc (ORGO). have?

Organogenesis Holdings Inc (ORGO) has 869 emplpoyees as of January 10 2026.

What is Organogenesis Holdings Inc (ORGO) market cap?

Today ORGO has the market capitalization of 534.30M USD.